LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akciju saraksts・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Slēgts

SektorsVeselības aprūpe

53.29 0.62

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

52.46

Max

53.32

Galvenie mērījumi
By Trading Economics
Ienākumi	-457M -31M
Pārdošana	-49M 776M
P/E Sektora vidējais	19.814 77.671
EPS	1.44
Peļņas marža	-3.961
Darbinieki	3,040
EBITDA	-324M -5.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+62.07% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-221M 10B
Iepriekšējā atvēršanas cena	52.67
Iepriekšējā slēgšanas cena	53.29

Ziņu noskaņojums

By Acuity

60%

40%

311 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

59.405 / 62.19 Atbalsts un pretestība

BioMarin Pharmaceutical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. dec. 16:42 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

2025. g. 12. dec. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025. g. 12. dec. 22:52 UTC

Tirgus saruna

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025. g. 12. dec. 22:32 UTC

Peļņas

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 20:45 UTC

Peļņas

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025. g. 12. dec. 20:41 UTC

Tirgus saruna

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025. g. 12. dec. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025. g. 12. dec. 19:23 UTC

Peļņas

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025. g. 12. dec. 18:35 UTC

Iegādes, apvienošanās, pārņemšana

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025. g. 12. dec. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025. g. 12. dec. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025. g. 12. dec. 17:49 UTC

Peļņas

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025. g. 12. dec. 17:34 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

2025. g. 12. dec. 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing of the Transaction Is Expected in the First Half of 2026

2025. g. 12. dec. 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

2025. g. 12. dec. 17:32 UTC

Iegādes, apvienošanās, pārņemšana

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

2025. g. 12. dec. 17:31 UTC

Iegādes, apvienošanās, pārņemšana

Orange to Buy the Stake for EU4.25B in Cash

2025. g. 12. dec. 17:24 UTC

Tirgus saruna

Argentina Predicts Record Wheat Crop -- Market Talk

2025. g. 12. dec. 17:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 17:18 UTC

Tirgus saruna

Peļņas

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

2025. g. 12. dec. 17:09 UTC

Tirgus saruna

Broadcom Investors Were Primed to Sell Shares -- Market Talk

2025. g. 12. dec. 17:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 12. dec. 16:47 UTC

Tirgus saruna

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

2025. g. 12. dec. 16:39 UTC

Tirgus saruna

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

2025. g. 12. dec. 16:27 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

2025. g. 12. dec. 16:15 UTC

Peļņas

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

2025. g. 12. dec. 15:35 UTC

Peļņas

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 14:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

BioMarin Pharmaceutical Inc Prognoze

Cenas mērķis

By TipRanks

62.07% augšup

Prognoze 12 mēnešiem

Vidējais 85.88 USD 62.07%

Augstākais 120 USD

Zemākais 55 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi BioMarin Pharmaceutical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam BioMarin Pharmaceutical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.405 / 62.19Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Noskaņojums

By Acuity

311 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.